omniture
FORESEE PHARMACEUTICALS CO., LTD.

Latest News

Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg

TAIPEI, , March 29, 2019 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), ...

2019-03-30 04:06 785

Foresee Pharmaceuticals Announces Successful Topline Results from Phase 3 Registration Study of LMIS 25 mg in Prostate Cancer

TAIPEI, , February 21, 2019 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"...

2019-02-21 18:30 640

Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare

TAIPEI, , Feb. 11, 2019 /PRNewswire/ -- An exclusive license agreement for the commercialisation of...

2019-02-11 18:30 519

Foresee Pharmaceuticals Announces Completion of Last Patient Visit in Registration Phase 3 Study of LMIS 25 mg (fp-001) for the Treatment of Advanced Prostate Cancer

TAIPEI, , Nov. 26, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) today announce...

2018-11-26 21:30 428

Foresee Pharmaceuticals Announces Sr. VP of Pharmaceutics and Manufacturing Appointment

TAIPEI, , Nov. 15, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), a...

2018-11-15 20:33 320

Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-045, a Potent ALDH2 Activator

TAIPEI, , July 26, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), a...

2018-07-26 19:30 590

Foresee Pharmaceuticals and Megapharm Announce License and Distribution Agreement

TAIPEI, and RAANANA, Israel, Jan. 3, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576....

2018-01-03 20:02 327

Foresee Pharmaceuticals Announces Results from Phase 1 Clinical Studies

TAIPEI, , Dec. 4, 2017 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), an...

2017-12-04 23:06 405

Foresee Pharmaceuticals and TRPharm Announce License and Distribution Agreement

TAIPEI, and ISTANBUL, Sept. 27, 2017 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ...

2017-09-27 19:56 2105

Foresee Pharmaceuticals Announces CEO Appointment

TAIPEI, , July 31, 2017 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), ...

2017-07-31 18:53 1910

Foresee Pharmaceuticals Announces Key Executive Appointments

TAIPEI, , April 13, 2017 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), a...

2017-04-13 16:00 2244

Foresee Pharmaceuticals Announces Completion of USD16M Fundraising

TAIPEI, , April 5, 2017 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), an...

2017-04-05 19:57 1040

Foresee Announces Successful Completion of Scientific Advice Discussions with German Federal Institute for Drugs and Medical Devices (BfArM) for FP-001 LMIS 50 mg

TAIPEI, , Feb. 6, 2017 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee") toda...

2017-02-06 19:59 1584

Foresee Pharmaceuticals Announces Top-Line Results from Phase 3 Registration Study in Advanced Prostate Cancer

TAIPEI, , Jan. 26, 2017 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), an...

2017-01-27 10:26 3491